Neutrophil to Lymphocyte Ratio in Acute Exacerbation of Chronic Obstructive Pulmonary Disease

NCT07125352 | Recruiting

• 1 other identifier: FMASU R123/2025
• Study Type: observational
• Target: 190
• Locations: 1 country
• Sites: 1

Brief Summary

Chronic obstructive pulmonary disease (COPD) stands as one of the leading causes of mortality worldwide. Acute exacerbations of COPD (AECOPD) lead to rapid respiratory function decline and worsened disease status. Despite recent studies, the ability of the neutrophil-to-lymphocyte ratio (NLR) to predict outcomes in patients with COPD remains controversial. It remains controversial whether NLR can predict clinical outcomes in hospitalized patients with AECOPD. Therefore, this study was conducted to investigate the predictive value of NLR for severity, adverse outcomes in hospitalized patients with AECOPD, and predicting treatment response in patients with AECOPD

Conditions

Chronic Obstructive Pulmonary Disease Exacerbation

Outcome Measures

Primary Outcomes (1)

• The ratio of neutrophils to lymphocytes in (%) in the CBC

  investigate the relation between this % ratio and severity of symptoms and adverse hospitalization outcomes in hospitalized patients with AECOPD

  baseline

Secondary Outcomes (1)

• The ratio of neutrophils to lymphocytes in (%) in the CBC

  3 months

Interventions

neutrophil lymphocyte ratio in COPD patients OTHER

Neutrophil lymphocyte ratio in determining severity and prognosis in exacerbation of COPD patients

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients aged 18 and above Patients who will be admitted at Chest department, Ain-Shams University Hospitals diagnosed with AECOPD based on the global initiative for chronic obstructive lung disease 2024 criteria

You may qualify if:

• Patients aged 18 and above, Patients who will be admitted at the Chest department, Ain-Shams University Hospitals, diagnosed with AECOPD based on the Global Initiative for Chronic Obstructive Lung Disease 2024 criteria

You may not qualify if:

• Patients who refused treatment.
• COPD patients with Malignancy, hematological disorders

Sponsors & Collaborators

• Ain Shams University: lead

Study Sites (1)

Ain Shams University

Cairo, Abbasyea, 02, Egypt

RECRUITING

Central Study Contacts

Hieba G Ezzelregal, MD

CONTACT

01002041611; hiebagamal24@med.asu.edu.eg

mona A alhady, MD

CONTACT

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant professor

Study Record Dates

• First Submitted: August 5, 2025
• First Posted: August 15, 2025
• Study Start: May 20, 2025
• Primary Completion: December 1, 2025
• Study Completion: March 1, 2026
• Last Updated: August 15, 2025

Record last verified: 2025-08

Locations

EG (1)